A blue cone is sitting on a white surface.

Challenges in Sustaining Weight Loss Medications

 

 

According to a recent study published in JAMA Network Open , nearly 65% of individuals using weight loss medications like Ozempic or Victoza discontinued them within a year. Specifically, those without diabetes were more likely to halt usage, with costs being a significant factor.

Researchers from Truveta and the University of Pennsylvania highlight that while health insurers typically cover GLP-1 medications for diabetes, coverage for weight loss is inconsistent. This results in prohibitive costs, often exceeding $1,000 monthly. Those with higher incomes and fewer side effects were more inclined to continue their medications.

Dr. Tricia Rodriguez, lead author, noted, "The high discontinuation rate underscores insurance and cost challenges, making these drugs less accessible for those without Type 2 diabetes." The study involved over 125,000 adults starting GLP-1 drugs between January 2018 and December 2023. Drugs like Novo Nordisk's semaglutide, under the brand names Ozempic for diabetes and Wegovy for weight loss, and Eli Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbpund for weight loss, were analyzed.

Side effects, particularly digestive issues, prompted some to quit. However, those witnessing significant weight loss results tend to persist with the treatment. The study also found that individuals who regained weight post-treatment often attempt a second round.

Insurance coverage remains a significant hurdle. Many employers offer limited obesity medication coverage, and states like North Carolina have withdrawn it altogether. Only 1% of the Affordable Care Act marketplace plans currently cover these medications. Medicare restricts coverage to those with diabetes or heart conditions, though a proposed plan might extend coverage to more enrollees by 2026.

Ezekiel Emanuel from the University of Pennsylvania emphasizes that the effectiveness of these weight loss drugs hinges on their affordability and accessibility.


Share by: